Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Key updates from the interim analysis of the FLAIR trial

Peter Hillmen • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax
FLAIR

In this video, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, shares some key results from the interim analysis of the Phase III FLAIR trial (ISRCTN01844152) evaluating the combination of ibrutinib plus venetoclax versus ibrutinib alone in patients with chronic lymphocytic leukemia (CLL). Prof. Hillmen highlights the rate of measurable residual disease (MRD) negative responses observed in patients, which was higher in the ibrutinib plus venetoclax arm. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Peter Hillmen

1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022
0:58
ALPINE: QoL in patients with R/R CLL treated with zanubrutinib vs ibrutinib
Peter Hillmen • 10 Jun 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals